Uptake and adverse events following mpox vaccination rollout in Nigeria

AUTHORS

E. Okpokoro¹, E.P. Ekele¹, R. Bello¹, O.S. Attah¹, A. Akigbogun¹, C.P. Obi¹, E. Kombu¹, O. Ayorinde¹, O. Nicholas², B. Abaye³, A. Kolawole⁴, A. Abdullahi⁵, J. Onyemata¹, S. Adebajo⁶, D. Tan⁷, S. Mishra⁷, J. Kwong^7,8, A. Abimiku^9,1, R. Audu¹⁰


INSTITUTIONS

¹International Research Center of Excellence, Institute of Human Virology, Nigeria (IHVN), Abuja, Nigeria, ²Federal Capital Territory Primary Healthcare Board, Abuja, Nigeria, ³Bayelsa State Ministry of Health, Public Health, Yenagoa, Nigeria, ⁴National Primary Healthcare Development Agency (NPHCDA), Abuja, Nigeria, ⁵University of Cambridge, Department of Medicine, Jeffrey Cheah Biomedical Centre, Cambridge, United Kingdom, ⁶University of Maryland, Baltimore, United States, ⁷Unity Health Toronto, Division of Infectious Diseases, Toronto, Canada, ⁸University Health Network, Department of Family and Community Medicine, Toronto, Canada, ⁹Institute of Human Virology University of Maryland School of Medicine, Baltimore, United States, ¹⁰Nigerian Institute of Medical Research, Yaba, Nigeria